Log In
Print this Print this

buprenorphine (Probuphine)

  Manage Alerts
Collapse Summary General Information
Company Titan Pharmaceuticals Inc.
DescriptionSubcutaneous rod implant for continuous 6-month delivery of buprenorphine using ProNeura technology
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationAddiction
Indication DetailsTreat opioid dependence
Regulatory Designation U.S. - Priority Review (Treat opioid dependence)
Partner Braeburn Pharmaceuticals S.p.r.l.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today